Key facts
- Notable investors include DeveloPPP Ventures, African Diaspora Network, Aruwa Capital Management, Jaza Rift Ventures, Tekedia Capital.
- Revna Biosciences has filed 1 Form D with the SEC, most recently Dec 2024 ( sold).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Revna Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Revna Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Revna Biosciences
Developer of molecular diagnostics products and services designed for administering precision medicine. The company operates multidisciplinary laboratories and a biospecimen archiving unit, they incorporate insights from in-house molecular diagnostics and clinical bioinformatics cores, enabling healthcare professionals to achieve better health outcomes.
- Sector
- Healthcare
- HQ
- Accra, Ghana
- Founded
- 2017
- Employees
- 28
- Website
- revnabio.com/
- Ownership
- Privately Held (backing)
Revna Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Revna Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Revna Biosciences in its N-PORT filings yet. We sweep new filings monthly.